Stephen Gitelman, MD
Professor
Pediatrics
School of Medicine

He also has broad research interests in defining subtypes of T1D, optimizing clinical care of those living with diabetes, and in mentoring the next generation of physician scientists in Pediatric Endocrinology.

• Hydroxychloroquine in Stage 1 Type 1 Diabetes.
  Diabetes care 2023 Libman I, Bingley PJ, Becker D, Buckner JH, DiMeglio LA, Gitelman SE, Greenbaum C, Haller MJ, Ismail HM, Krischer J, Moore WV, Moran A, Muir AB, Raman V, Steck AK, Toledo FGS, Wentworth J, Wherrett D,…
• Teplizumab and β-Cell Function in Newly Diagnosed Type 1 Diabetes.
  The New England journal of medicine 2023 Ramos EL, Dayan CM, Chatenoud L, Sumnik Z, Simmons KM, Szypowska A, Gitelman SE, Knecht LA, Niemoeller E, Tian W, Herold KC, PROTECT Study Investigators
• Disease-modifying therapies and features linked to treatment response in type 1 diabetes prevention: a systematic review.
  Communications medicine 2023 Felton JL, Griffin KJ, Oram RA, Speake C, Long SA, Onengut-Gumuscu S, Rich SS, Monaco GSF, Evans-Molina C, DiMeglio LA, Ismail HM, Steck AK, Dabelea D, Johnson RK, Urazbayeva M, Gitelman S, Wentworth …
• Second international consensus report on gaps and opportunities for the clinical translation of precision diabetes medicine.
  Nature medicine 2023 Tobias DK, Merino J, Ahmad A, Aiken C, Benham JL, Bodhini D, Clark AL, Colclough K, Corcoy R, Cromer SJ, Duan D, Felton JL, Francis EC, Gillard P, Gingras V, Gaillard R, Haider E, Hughes A, Ikle JM, …
• Teplizumab: A Disease-Modifying Therapy for Type 1 Diabetes That Preserves β-Cell Function.
  Diabetes care 2023 Herold KC, Gitelman SE, Gottlieb PA, Knecht LA, Raymond R, Ramos EL
• β-Cell Glucose Sensitivity to Assess Changes in β-Cell Function in Recent-Onset Stage 3 Type 1 Diabetes.
  Diabetes 2023 Gitelman SE, Evans-Molina C, Guolo A, Mari A, Ferrannini E
• Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial.
  Diabetes care 2023 Russell WE, Bundy BN, Anderson MS, Cooney LA, Gitelman SE, Goland RS, Gottlieb PA, Greenbaum CJ, Haller MJ, Krischer JP, Libman IM, Linsley PS, Long SA, Lord SM, Moore DJ, Moore WV, Moran AM, Muir AB,…
• Type 1 Diabetes Prevention: a systematic review of studies testing disease-modifying therapies and features linked to treatment response.
  medRxiv : the preprint server for health sciences 2023 Felton JL, Griffin KJ, Oram RA, Speake C, Long SA, Onengut-Gumuscu S, Rich SS, Monaco GS, Evans-Molina C, DiMeglio LA, Ismail HM, Steck AK, Dabelea D, Johnson RK, Urazbayeva M, Gitelman S, Wentworth …
• Real-Time Continuous Glucose Monitoring in Adolescents and Young Adults With Type 2 Diabetes Can Improve Quality of Life.
  Journal of diabetes science and technology 2022 Chesser H, Srinivasan S, Puckett C, Gitelman SE, Wong JC
• The Transition From a Compensatory Increase to a Decrease in C-peptide During the Progression to Type 1 Diabetes and Its Relation to Risk.
  Diabetes care 2022 Ismail HM, Cuthbertson D, Gitelman SE, Skyler JS, Steck AK, Rodriguez H, Atkinson M, Nathan BM, Redondo MJ, Herold KC, Evans-Molina C, DiMeglio LA, Sosenko J, DPT-1 and TrialNet Study Groups
• Preferences for Risks and Benefits of Islet Cell Transplantation for Persons With Type 1 Diabetes With History of Episodes of Severe Hypoglycemia: A Discrete-Choice Experiment to Inform Regulatory Decisions.
  Transplantation 2022 Wilson L, Kwok T, Ma Y, Wong J, Ho M, Ionova Y, McGrath M, Mueller MM, Gitelman SE, Irony T
• IL-6 receptor blockade does not slow β cell loss in new-onset type 1 diabetes.
  JCI insight 2021 Greenbaum CJ, Serti E, Lambert K, Weiner LJ, Kanaparthi S, Lord S, Gitelman SE, Wilson DM, Gaglia JL, Griffin KJ, Russell WE, Raskin P, Moran A, Willi SM, Tsalikian E, DiMeglio LA, Herold KC, Moore WV…
• The effect of low-dose IL-2 and Treg adoptive cell therapy in patients with type 1 diabetes.
  JCI insight 2021 Dong S, Hiam-Galvez KJ, Mowery CT, Herold KC, Gitelman SE, Esensten JH, Liu W, Lares AP, Leinbach AS, Lee M, Nguyen V, Tamaki SJ, Tamaki W, Tamaki CM, Mehdizadeh M, Putnam AL, Spitzer MH, Ye CJ, Tang …
• Simplifying prediction of disease progression in pre-symptomatic type 1 diabetes using a single blood sample.
  Diabetologia 2021 Bediaga NG, Li-Wai-Suen CSN, Haller MJ, Gitelman SE, Evans-Molina C, Gottlieb PA, Hippich M, Ziegler AG, Lernmark A, DiMeglio LA, Wherrett DK, Colman PG, Harrison LC, Wentworth JM
• Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
  The lancet. Diabetes & endocrinology 2021 Gitelman SE, Bundy BN, Ferrannini E, Lim N, Blanchfield JL, DiMeglio LA, Felner EI, Gaglia JL, Gottlieb PA, Long SA, Mari A, Mirmira RG, Raskin P, Sanda S, Tsalikian E, Wentworth JM, Willi SM, …
• Youth with Type 1 Diabetes Had Improvement in Continuous Glucose Monitoring Metrics During the COVID-19 Pandemic.
  Diabetes technology & therapeutics 2021 Abdulhussein FS, Chesser H, Boscardin WJ, Gitelman SE, Wong JC
• Low-Dose ATG/GCSF in Established Type 1 Diabetes: A Five-Year Follow-up Report.
  Diabetes 2021 Lin A, Mack JA, Bruggeman B, Jacobsen LM, Posgai AL, Wasserfall CH, Brusko TM, Atkinson MA, Gitelman SE, Gottlieb PA, Gurka MJ, Mathews CE, Schatz DA, Haller MJ
• Continuous Glucose Monitoring to Diagnose Hypoglycemia Due to Late Dumping Syndrome in Children After Gastric Surgeries.
  Journal of the Endocrine Society 2021 Chesser H, Abdulhussein F, Huang A, Lee JY, Gitelman SE
• Comparing Beta Cell Preservation Across Clinical Trials in Recent-Onset Type 1 Diabetes.
  Diabetes technology & therapeutics 2020 Jacobsen LM, Bundy BN, Greco MN, Schatz DA, Atkinson MA, Brusko TM, Mathews CE, Herold KC, Gitelman SE, Krischer JP, Haller MJ
• Exenatide extended release in patients with type 1 diabetes with and without residual insulin production.
  Diabetes, obesity & metabolism 2020 Herold KC, Reynolds J, Dziura J, Baidal D, Gaglia J, Gitelman SE, Gottlieb PA, Marks J, Philipson LH, Pop-Busui R, Weinstock RS
• Clinical trial data validate the C-peptide estimate model in type 1 diabetes.
  Diabetologia 2020 Wentworth JM, Bediaga NG, Gitelman SE, Evans-Molina C, Gottlieb PA, Colman PG, Haller MJ, Harrison LC
• Excess BMI Accelerates Islet Autoimmunity in Older Children and Adolescents.
  Diabetes care 2020 Ferrara-Cook C, Geyer SM, Evans-Molina C, Libman IM, Becker DJ, Gitelman SE, Redondo MJ, Type 1 Diabetes TrialNet Study Group
• Immunomodulatory activity of humanized anti-IL-7R monoclonal antibody RN168 in subjects with type 1 diabetes.
  JCI insight 2019 Herold KC, Bucktrout SL, Wang X, Bode BW, Gitelman SE, Gottlieb PA, Hughes J, Joh T, McGill JB, Pettus JH, Potluri S, Schatz D, Shannon M, Udata C, Wong G, Levisetti M, Ganguly BJ, Garzone PD, RN168 …
• Introducing the Endotype Concept to Address the Challenge of Disease Heterogeneity in Type 1 Diabetes.
  Diabetes care 2019 Battaglia M, Ahmed S, Anderson MS, Atkinson MA, Becker D, Bingley PJ, Bosi E, Brusko TM, DiMeglio LA, Evans-Molina C, Gitelman SE, Greenbaum CJ, Gottlieb PA, Herold KC, Hessner MJ, Knip M, Jacobsen L,…
• Elicited and pre-existing anti-Neu5Gc antibodies differentially affect human endothelial cells transcriptome.
  Xenotransplantation 2019 Le Berre L, Danger R, Mai HL, Amon R, Leviatan Ben-Arye S, Bruneau S, Senage T, Perreault H, Teraiya M, Nguyen TVH, Le Tourneau T, Yu H, Chen X, Galli C, Roussel JC, Manez R, Costa C, Brouard S, …
• An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes.
  The New England journal of medicine 2019 Herold KC, Bundy BN, Long SA, Bluestone JA, DiMeglio LA, Dufort MJ, Gitelman SE, Gottlieb PA, Krischer JP, Linsley PS, Marks JB, Moore W, Moran A, Rodriguez H, Russell WE, Schatz D, Skyler JS, …
• Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA1c, and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial Data.
  Diabetes 2019 Haller MJ, Long SA, Blanchfield JL, Schatz DA, Skyler JS, Krischer JP, Bundy BN, Geyer SM, Warnock MV, Miller JL, Atkinson MA, Becker DJ, Baidal DA, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, …
• Beta cell function in type 1 diabetes determined from clinical and fasting biochemical variables.
  Diabetologia 2018 Wentworth JM, Bediaga NG, Giles LC, Ehlers M, Gitelman SE, Geyer S, Evans-Molina C, Harrison LC, Type 1 Diabetes TrialNet Study Group, Immune Tolerance Network Study Group
• Low-Dose Anti-Thymocyte Globulin (ATG) Preserves β-Cell Function and Improves HbA1c in New-Onset Type 1 Diabetes.
  Diabetes care 2018 Haller MJ, Schatz DA, Skyler JS, Krischer JP, Bundy BN, Miller JL, Atkinson MA, Becker DJ, Baidal D, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Herold KC, Marks JB, Moran A, Rodriguez H, Russell…
• Glycan microarray reveal induced IgGs repertoire shift against a dietary carbohydrate in response to rabbit anti-human thymocyte therapy.
  Oncotarget 2017 Amon R, Ben-Arye SL, Engler L, Yu H, Lim N, Berre LL, Harris KM, Ehlers MR, Gitelman SE, Chen X, Soulillou JP, Padler-Karavani V
• The Role of Age and Excess Body Mass Index in Progression to Type 1 Diabetes in At-Risk Adults.
  The Journal of clinical endocrinology and metabolism 2017 Ferrara CT, Geyer SM, Evans-Molina C, Libman IM, Becker DJ, Wentworth JM, Moran A, Gitelman SE, Redondo MJ, Type 1 Diabetes TrialNet Study Group
• A new familial form of a late-onset, persistent hyperinsulinemic hypoglycemia of infancy caused by a novel mutation in KCNJ11.
  Channels (Austin, Tex.) 2017 Yang YY, Long RK, Ferrara CT, Gitelman SE, German MS, Yang SB
• Type 1 Diabetes and Celiac Disease: Causal Association or True, True, Unrelated?
  Pediatrics 2017 Ferrara CT, Gitelman SE
• Anti-Gal and Anti-Neu5Gc Responses in Nonimmunosuppressed Patients After Treatment With Rabbit Antithymocyte Polyclonal IgGs.
  Transplantation 2017 Salama A, Evanno G, Lim N, Rousse J, Le Berre L, Nicot A, Bach JM, Brouard S, Harris KM, Ehlers MR, Gitelman SE, Soulillou JP
• Excess BMI in Childhood: A Modifiable Risk Factor for Type 1 Diabetes Development?
  Diabetes care 2017 Ferrara CT, Geyer SM, Liu YF, Evans-Molina C, Libman IM, Besser R, Becker DJ, Rodriguez H, Moran A, Gitelman SE, Redondo MJ, Type 1 Diabetes TrialNet Study Group
• Association Between Blood Pressure and Adverse Renal Events in Type 1 Diabetes.
  Diabetes care 2016 Ku E, McCulloch CE, Mauer M, Gitelman SE, Grimes BA, Hsu CY
• Antithymocyte Globulin Plus G-CSF Combination Therapy Leads to Sustained Immunomodulatory and Metabolic Effects in a Subset of Responders With Established Type 1 Diabetes.
  Diabetes 2016 Haller MJ, Gitelman SE, Gottlieb PA, Michels AW, Perry DJ, Schultz AR, Hulme MA, Shuster JJ, Zou B, Wasserfall CH, Posgai AL, Mathews CE, Brusko TM, Atkinson MA, Schatz DA
• Regulatory T cell therapy for type 1 diabetes: May the force be with you.
  Journal of autoimmunity 2016 Gitelman SE, Bluestone JA
• Two- and Four-Hour Tests Differ in Capture of C-Peptide Responses to a Mixed Meal in Type 1 Diabetes.
  Diabetes care 2016 Boyle KD, Keyes-Elstein L, Ehlers MR, McNamara J, Rigby MR, Gitelman SE, Weiner LJ, Much KL, Herold KC
• Antithymocyte globulin therapy for patients with recent-onset type 1 diabetes: 2 year results of a randomised trial.
  Diabetologia 2016 Gitelman SE, Gottlieb PA, Felner EI, Willi SM, Fisher LK, Moran A, Gottschalk M, Moore WV, Pinckney A, Keyes-Elstein L, Harris KM, Kanaparthi S, Phippard D, Ding L, Bluestone JA, Ehlers MR, ITN START …
• Type 1 diabetes immunotherapy using polyclonal regulatory T cells.
  Science translational medicine 2015 Bluestone JA, Buckner JH, Fitch M, Gitelman SE, Gupta S, Hellerstein MK, Herold KC, Lares A, Lee MR, Li K, Liu W, Long SA, Masiello LM, Nguyen V, Putnam AL, Rieck M, Sayre PH, Tang Q
• Defining pathways for development of disease-modifying therapies in children with type 1 diabetes: a consensus report.
  Diabetes care 2015 Wherrett DK, Chiang JL, Delamater AM, DiMeglio LA, Gitelman SE, Gottlieb PA, Herold KC, Lovell DJ, Orchard TJ, Ryan CM, Schatz DA, Wendler DS, Greenbaum CJ, Type 1 Diabetes TrialNet Study Group
• Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients.
  The Journal of clinical investigation 2015 Rigby MR, Harris KM, Pinckney A, DiMeglio LA, Rendell MS, Felner EI, Dostou JM, Gitelman SE, Griffin KJ, Tsalikian E, Gottlieb PA, Greenbaum CJ, Sherry NA, Moore WV, Monzavi R, Willi SM, Raskin P, …
• Anti-thymocyte globulin/G-CSF treatment preserves β cell function in patients with established type 1 diabetes.
  The Journal of clinical investigation 2014 Haller MJ, Gitelman SE, Gottlieb PA, Michels AW, Rosenthal SM, Shuster JJ, Zou B, Brusko TM, Hulme MA, Wasserfall CH, Mathews CE, Atkinson MA, Schatz DA
• Recommendations for the definition of clinical responder in insulin preservation studies.
  Diabetes 2014 Beam CA, Gitelman SE, Palmer JP, Type 1 Diabetes TrialNet Study Group
• Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatment.
  Diabetes care 2013 Orban T, Bundy B, Becker DJ, Dimeglio LA, Gitelman SE, Goland R, Gottlieb PA, Greenbaum CJ, Marks JB, Monzavi R, Moran A, Peakman M, Raskin P, Russell WE, Schatz D, Wherrett DK, Wilson DM, Krischer JP…
• Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial.
  The lancet. Diabetes & endocrinology 2013 Rigby MR, DiMeglio LA, Rendell MS, Felner EI, Dostou JM, Gitelman SE, Patel CM, Griffin KJ, Tsalikian E, Gottlieb PA, Greenbaum CJ, Sherry NA, Moore WV, Monzavi R, Willi SM, Raskin P, Moran A, Russell…
• B-lymphocyte depletion with rituximab and β-cell function: two-year results.
  Diabetes care 2013 Pescovitz MD, Greenbaum CJ, Bundy B, Becker DJ, Gitelman SE, Goland R, Gottlieb PA, Marks JB, Moran A, Raskin P, Rodriguez H, Schatz DA, Wherrett DK, Wilson DM, Krischer JP, Skyler JS, Type 1 Diabetes…
• Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial.
  The lancet. Diabetes & endocrinology 2013 Gitelman SE, Gottlieb PA, Rigby MR, Felner EI, Willi SM, Fisher LK, Moran A, Gottschalk M, Moore WV, Pinckney A, Keyes-Elstein L, Aggarwal S, Phippard D, Sayre PH, Ding L, Bluestone JA, Ehlers MR, …
• Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders.
  Diabetes 2013 Herold KC, Gitelman SE, Ehlers MR, Gottlieb PA, Greenbaum CJ, Hagopian W, Boyle KD, Keyes-Elstein L, Aggarwal S, Phippard D, Sayre PH, McNamara J, Bluestone JA, AbATE Study Team
• Altering the course of type 1 diabetes: an update on prevention and new-onset clinical trials.
  Pediatric diabetes 2013 Thomas HR, Gitelman SE
• Combined pancreatic islet and kidney transplantation in a child with unstable type 1 diabetes and end-stage renal disease.
  American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2013 Benedict KA, Moassesfar S, Adi S, Gitelman SE, Brennan JL, McEnhill M, Stock PG, Portale AA, Posselt AM
• Comparison of autoantibody-positive and autoantibody-negative pediatric participants enrolled in the T1D Exchange clinic registry.
  Journal of diabetes 2013 Gerard-Gonzalez A, Gitelman SE, Cheng P, Dubose SN, Miller KM, Olson BA, Redondo MJ, Steck AK, Beck RW
• Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials.
  Lancet (London, England) 2013 Moran A, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Greenbaum CJ, Herold KC, Marks JB, Raskin P, Sanda S, Schatz D, Wherrett DK, Wilson DM, Krischer JP, Skyler JS, Type 1 Diabetes …
• A cross-sectional study of osteocalcin and body fat measures among obese adolescents.
  Obesity (Silver Spring, Md.) 2013 Lenders CM, Lee PD, Feldman HA, Wilson DM, Abrams SH, Gitelman SE, Klish WJ, Wertz MS, Taylor GA, Alongi RT, Chen TC, Holick MF, Elisabeth Glaser Pediatric Research Network Obesity Study Group
• Immune therapy and β-cell death in type 1 diabetes.
  Diabetes 2013 Lebastchi J, Deng S, Lebastchi AH, Beshar I, Gitelman S, Willi S, Gottlieb P, Akirav EM, Bluestone JA, Herold KC
• Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial.
  Diabetologia 2012 Herold KC, Gitelman SE, Willi SM, Gottlieb PA, Waldron-Lynch F, Devine L, Sherr J, Rosenthal SM, Adi S, Jalaludin MY, Michels AW, Dziura J, Bluestone JA
• Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data.
  Diabetes 2012 Greenbaum CJ, Beam CA, Boulware D, Gitelman SE, Gottlieb PA, Herold KC, Lachin JM, McGee P, Palmer JP, Pescovitz MD, Krause-Steinrauf H, Skyler JS, Sosenko JM, Type 1 Diabetes TrialNet Study Group
• Persistent elevation of urine aquaporin-2 during water loading in a child with nephrogenic syndrome of inappropriate antidiuresis (NSIAD) caused by a R137L mutation in the V2 vasopressin receptor.
  International journal of pediatric endocrinology 2012 Cheung CC, Cadnapaphornchai MA, Ranadive SA, Gitelman SE, Rosenthal SM
• Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial.
  Lancet (London, England) 2011 Orban T, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Greenbaum CJ, Marks JB, Monzavi R, Moran A, Raskin P, Rodriguez H, Russell WE, Schatz D, Wherrett D, Wilson DM, Krischer …
• Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial.
  Lancet (London, England) 2011 Wherrett DK, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Greenbaum CJ, Herold KC, Marks JB, Monzavi R, Moran A, Orban T, Palmer JP, Raskin P, Rodriguez H, Schatz D, Wilson DM,…
• Detecting and treating hyperlipidemia in children with type 1 diabetes mellitus: are standard guidelines applicable to this special population?
  Pediatric diabetes 2010 Glaser NS, Geller DH, Haqq A, Gitelman S, Malloy M, Lawson Wilkins Pediatric Endocrine Society Committee on Drugs and Therapeutics
• Impact of an interactive online nursing educational module on insulin errors in hospitalized pediatric patients.
  Diabetes care 2010 Sullivan MM, O'Brien CR, Gitelman SE, Shapiro SE, Rushakoff RJ
• Functional characterization of vasopressin type 2 receptor substitutions (R137H/C/L) leading to nephrogenic diabetes insipidus and nephrogenic syndrome of inappropriate antidiuresis: implications for treatments.
  Molecular pharmacology 2010 Rochdi MD, Vargas GA, Carpentier E, Oligny-Longpré G, Chen S, Kovoor A, Gitelman SE, Rosenthal SM, von Zastrow M, Bouvier M
• Long-term outcomes in a family with nephrogenic syndrome of inappropriate antidiuresis.
  International journal of pediatric endocrinology 2010 Cho YH, Gitelman S, Rosenthal S, Ambler G
• Rituximab, B-lymphocyte depletion, and preservation of beta-cell function.
  The New England journal of medicine 2009 Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, Becker DJ, Gitelman SE, Goland R, Gottlieb PA, Marks JB, McGee PF, Moran AM, Raskin P, Rodriguez H, Schatz DA, Wherrett D, Wilson DM, Lachin JM, Skyler …
• Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus.
  JAMA 2009 Gitelman SE, Haller MJ, Schatz D
• Relation of body fat indexes to vitamin D status and deficiency among obese adolescents.
  The American journal of clinical nutrition 2009 Lenders CM, Feldman HA, Von Scheven E, Merewood A, Sweeney C, Wilson DM, Lee PD, Abrams SH, Gitelman SE, Wertz MS, Klish WJ, Taylor GA, Chen TC, Holick MF, Elizabeth Glaser Pediatric Research Network …
• Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years.
  Clinical immunology (Orlando, Fla.) 2009 Herold KC, Gitelman S, Greenbaum C, Puck J, Hagopian W, Gottlieb P, Sayre P, Bianchine P, Wong E, Seyfert-Margolis V, Bourcier K, Bluestone JA, Immune Tolerance Network ITN007AI Study Group
• The effect of oral alpha-lipoic acid on oxidative stress in adolescents with type 1 diabetes mellitus.
  Pediatric diabetes 2008 Huang EA, Gitelman SE
• Congenital hyperinsulinism in an infant caused by a macroscopic insulin-producing lesion.
  Journal of pediatric endocrinology & metabolism : JPEM 2007 Bremer AA, Nobuhara KK, Gitelman SE
• Nephrogenic syndrome of inappropriate antidiuresis (NSIAD): a paradigm for activating mutations causing endocrine dysfunction.
  Pediatric endocrinology reviews : PER 2006 Rosenthal SM, Feldman BJ, Vargas GA, Gitelman SE
• Analysis of T-cell assays to measure autoimmune responses in subjects with type 1 diabetes: results of a blinded controlled study.
  Diabetes 2006 Seyfert-Margolis V, Gisler TD, Asare AL, Wang RS, Dosch HM, Brooks-Worrell B, Eisenbarth GS, Palmer JP, Greenbaum CJ, Gitelman SE, Nepom GT, Bluestone JA, Herold KC
• Nephrogenic syndrome of inappropriate antidiuresis: a novel disorder in water balance in pediatric patients.
  The American journal of medicine 2006 Gitelman SE, Feldman BJ, Rosenthal SM
• Oral urea for the treatment of chronic syndrome of inappropriate antidiuresis in children.
  The Journal of pediatrics 2006 Huang EA, Feldman BJ, Schwartz ID, Geller DH, Rosenthal SM, Gitelman SE
• Prevalence and characteristics of type 2 diabetes mellitus in 9-18 year-old children with diabetic ketoacidosis.
  Journal of pediatric endocrinology & metabolism : JPEM 2005 Sapru A, Gitelman SE, Bhatia S, Dubin RF, Newman TB, Flori H
• A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes.
  Diabetes 2005 Herold KC, Gitelman SE, Masharani U, Hagopian W, Bisikirska B, Donaldson D, Rother K, Diamond B, Harlan DM, Bluestone JA
• Nephrogenic syndrome of inappropriate antidiuresis.
  The New England journal of medicine 2005 Feldman BJ, Rosenthal SM, Vargas GA, Fenwick RG, Huang EA, Matsuda-Abedini M, Lustig RH, Mathias RS, Portale AA, Miller WL, Gitelman SE
• A two-center randomized controlled feasibility trial of insulin pump therapy in young children with diabetes.
  Diabetes care 2005 Wilson DM, Buckingham BA, Kunselman EL, Sullivan MM, Paguntalan HU, Gitelman SE
• The use of a continuous glucose monitoring system in hypoglycemic disorders.
  Journal of pediatric endocrinology & metabolism : JPEM 2004 Conrad SC, Mastrototaro JJ, Gitelman SE
• Insulin secretion in type 1 diabetes.
  Diabetes 2004 Steele C, Hagopian WA, Gitelman S, Masharani U, Cavaghan M, Rother KI, Donaldson D, Harlan DM, Bluestone J, Herold KC
• Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus.
  The New England journal of medicine 2002 Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, Donaldson D, Gitelman SE, Harlan DM, Xu D, Zivin RA, Bluestone JA
• Transition from multiple daily injections to continuous subcutaneous insulin infusion in type 1 diabetes mellitus.
  The Journal of pediatrics 2002 Conrad SC, McGrath MT, Gitelman SE
• Increased incidence in post-transplant diabetes mellitus in children: a case-control analysis.
  Pediatric nephrology (Berlin, Germany) 2002 Greenspan LC, Gitelman SE, Leung MA, Glidden DV, Mathias RS
• Peptide mapping and characterisation of glycation patterns of the glima 38 antigen recognised by autoantibodies in Type I diabetic patients.
  Diabetologia 2000 Roll U, Turck CW, Gitelman SE, Rosenthal SM, Nolte MS, Masharani U, Ziegler AG, Baekkeskov S
• Inhibition of TGF-beta receptor signaling in osteoblasts leads to decreased bone remodeling and increased trabecular bone mass.
  Development (Cambridge, England) 1999 Filvaroff E, Erlebacher A, Ye J, Gitelman SE, Lotz J, Heillman M, Derynck R
• Smooth muscle expresses bone morphogenetic protein (Vgr-1/BMP-6) in human fetal intestine.
  Biology of the neonate 1999 Perr HA, Ye J, Gitelman SE
• Neonatal hyperinsulinism.
  Clinics in perinatology 1998 Schwitzgebel VM, Gitelman SE
• Long-term outcome in children and adolescents after transsphenoidal surgery for Cushing's disease.
  The Journal of clinical endocrinology and metabolism 1997 Devoe DJ, Miller WL, Conte FA, Kaplan SL, Grumbach MM, Rosenthal SM, Wilson CB, Gitelman SE
• Idiopathic hypothalamic diabetes insipidus, pituitary stalk thickening, and the occult intracranial germinoma in children and adolescents.
  The Journal of clinical endocrinology and metabolism 1997 Mootha SL, Barkovich AJ, Grumbach MM, Edwards MS, Gitelman SE, Kaplan SL, Conte FA
• Structure and sequence of the mouse Bmp6 gene.
  Mammalian genome : official journal of the International Mammalian Genome Society 1997 Gitelman SE, Kobrin M, Lee A, Fet V, Lyons K, Hogan BL, Derynck R
• Immunoreactive inhibin, müllerian inhibitory substance, and activin as biochemical markers for juvenile granulosa cell tumors.
  The Journal of pediatrics 1996 Silverman LA, Gitelman SE
• A promoter within intron 35 of the human C4A gene initiates abundant adrenal-specific transcription of a 1 kb RNA: location of a cryptic CYP21 promoter element?
  Human molecular genetics 1995 Tee MK, Babalola GO, Aza-Blanc P, Speek M, Gitelman SE, Miller WL
• Vgr-1/BMP-6 induces osteoblastic differentiation of pluripotential mesenchymal cells.
  Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research 1995 Gitelman SE, Kirk M, Ye JQ, Filvaroff EH, Kahn AJ, Derynck R
• Toward a molecular understanding of skeletal development.
  Cell 1995 Erlebacher A, Filvaroff EH, Gitelman SE, Derynck R
• Recombinant Vgr-1/BMP-6-expressing tumors induce fibrosis and endochondral bone formation in vivo.
  The Journal of cell biology 1994 Gitelman SE, Kobrin MS, Ye JQ, Lopez AR, Lee A, Derynck R
• Tenascin-X: a novel extracellular matrix protein encoded by the human XB gene overlapping P450c21B.
  The Journal of cell biology 1993 Bristow J, Tee MK, Gitelman SE, Mellon SH, Miller WL
• Abundant adrenal-specific transcription of the human P450c21A "pseudogene".
  The Journal of biological chemistry 1993 Bristow J, Gitelman SE, Tee MK, Staels B, Miller WL
• Mental retardation locus in Xp21 chromosome microdeletion.
  American journal of medical genetics 1993 Fries MH, Lebo RV, Schonberg SA, Golabi M, Seltzer WK, Gitelman SE, Golbus MS
• Congenital lipoid adrenal hyperplasia--genes for P450scc, side chain cleavage enzyme, are normal.
  The Journal of steroid biochemistry and molecular biology 1993 Saenger P, Lin D, Gitelman SE, Miller WL
• Analysis of the duplicated human C4/P450c21/X gene cluster.
  The Journal of steroid biochemistry and molecular biology 1992 Miller WL, Gitelman SE, Bristow J, Morel Y
• Mechanism and consequences of the duplication of the human C4/P450c21/gene X locus.
  Molecular and cellular biology 1992 Gitelman SE, Bristow J, Miller WL
• Mechanism and consequences of the duplication of the human C4/P450c21/gene X locus.
  Molecular and cellular biology 1992 Gitelman SE, Bristow J, Miller WL
• Normal genes for the cholesterol side chain cleavage enzyme, P450scc, in congenital lipoid adrenal hyperplasia.
  The Journal of clinical investigation 1991 Lin D, Gitelman SE, Saenger P, Miller WL
• Cloning of the LH/CG receptor: implications for a unique G-protein coupled receptor.
  Trends in endocrinology and metabolism: TEM 1990 Gitelman SE
• Transcript encoded on the opposite strand of the human steroid 21-hydroxylase/complement component C4 gene locus.
  Proceedings of the National Academy of Sciences of the United States of America 1989 Morel Y, Bristow J, Gitelman SE, Miller WL
• Purification of calmodulin from Chlamydomonas: calmodulin occurs in cell bodies and flagella.
  The Journal of cell biology 1980 Gitelman SE, Witman GB